Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin

K. Benjamin Garbutcheon-Singh; Benjamin W. J. Harper; Simon Myers; Janice R. Aldrich-Wright

doi:10.1039/c3mt00191a

Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin

K. Benjamin Garbutcheon-Singh, Benjamin W. J. Harper, Simon Myers, Janice R. Aldrich-Wright

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

With current chemotherapeutic treatment regimes often limited by adverse side effects, the synergistic combination of complexes with anticancer activity appears to offer a promising strategy for effective cancer treatment. This work investigates the anti-proliferative activity using a combination therapy approach where metallointercalators of the type [Pt(IL)(AL)]2+ (where IL is the intercalating ligand and AL is the ancillary ligand) are used in combination with currently approved anticancer drugs cisplatin and carboplatin and organic molecules buthionine-S,R-sulfoximine and 3-bromopyruvate. Synergistic relationships were observed, indicating a potential to decrease dose-dependent toxicity and improve therapeutic efficacy.

Original language	English
Pages (from-to)	126-131
Number of pages	6
Journal	Metallomics
Volume	6
Issue number	1
DOIs	https://doi.org/10.1039/c3mt00191a
Publication status	Published - 2014

Keywords

Glutathione
Chemotherapy
Drugs
Cytotoxicity
Inhibition
Resistance
Mechanisms
Origin
Agent

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/c3mt00191a

Cite this

@article{8de69bcd6f8a4eb896c634be6f770498,

title = "Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin",

abstract = "With current chemotherapeutic treatment regimes often limited by adverse side effects, the synergistic combination of complexes with anticancer activity appears to offer a promising strategy for effective cancer treatment. This work investigates the anti-proliferative activity using a combination therapy approach where metallointercalators of the type [Pt(IL)(AL)]2+ (where IL is the intercalating ligand and AL is the ancillary ligand) are used in combination with currently approved anticancer drugs cisplatin and carboplatin and organic molecules buthionine-S,R-sulfoximine and 3-bromopyruvate. Synergistic relationships were observed, indicating a potential to decrease dose-dependent toxicity and improve therapeutic efficacy.",

keywords = "Glutathione, Chemotherapy, Drugs, Cytotoxicity, Inhibition, Resistance, Mechanisms, Origin, Agent",

author = "Garbutcheon-Singh, {K. Benjamin} and Harper, {Benjamin W. J.} and Simon Myers and Aldrich-Wright, {Janice R.}",

year = "2014",

doi = "10.1039/c3mt00191a",

language = "English",

volume = "6",

pages = "126--131",

journal = "Metallomics",

issn = "1756-5901",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin

AU - Garbutcheon-Singh, K. Benjamin

AU - Harper, Benjamin W. J.

AU - Myers, Simon

AU - Aldrich-Wright, Janice R.

PY - 2014

Y1 - 2014

N2 - With current chemotherapeutic treatment regimes often limited by adverse side effects, the synergistic combination of complexes with anticancer activity appears to offer a promising strategy for effective cancer treatment. This work investigates the anti-proliferative activity using a combination therapy approach where metallointercalators of the type [Pt(IL)(AL)]2+ (where IL is the intercalating ligand and AL is the ancillary ligand) are used in combination with currently approved anticancer drugs cisplatin and carboplatin and organic molecules buthionine-S,R-sulfoximine and 3-bromopyruvate. Synergistic relationships were observed, indicating a potential to decrease dose-dependent toxicity and improve therapeutic efficacy.

AB - With current chemotherapeutic treatment regimes often limited by adverse side effects, the synergistic combination of complexes with anticancer activity appears to offer a promising strategy for effective cancer treatment. This work investigates the anti-proliferative activity using a combination therapy approach where metallointercalators of the type [Pt(IL)(AL)]2+ (where IL is the intercalating ligand and AL is the ancillary ligand) are used in combination with currently approved anticancer drugs cisplatin and carboplatin and organic molecules buthionine-S,R-sulfoximine and 3-bromopyruvate. Synergistic relationships were observed, indicating a potential to decrease dose-dependent toxicity and improve therapeutic efficacy.

KW - Glutathione

KW - Chemotherapy

KW - Drugs

KW - Cytotoxicity

KW - Inhibition

KW - Resistance

KW - Mechanisms

KW - Origin

KW - Agent

UR - http://handle.uws.edu.au:8081/1959.7/539110

U2 - 10.1039/c3mt00191a

DO - 10.1039/c3mt00191a

M3 - Article

C2 - 24084749

SN - 1756-5901

VL - 6

SP - 126

EP - 131

JO - Metallomics

JF - Metallomics

IS - 1

ER -

Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this